Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed and Radiation for Poor-Risk Stage III NSCLC
NCT00732303Phase 2Terminated
- Sponsor
- Hoosier Cancer Research Network
- Start
- Jan 2009
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Hoosier Cancer Research Network. Primary endpoint: Progression Free Survival at 24 months. Started Jan 2009; status: terminated.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00732303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00732303.